Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
| Revenue (TTM) | $29.37M |
| Gross Profit (TTM) | $-57.41M |
| EBITDA | $-99.55M |
| Operating Margin | -863.00% |
| Return on Equity | -46.30% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $1.05 |
| Book Value | $6.04 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | 7.97 |
| EV/Revenue | 3.499 |
| EV/EBITDA | -25.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.50% |
| Shares Outstanding | $28.42M |
| Float | $26.15M |
| % Insiders | 7.99% |
| % Institutions | 82.95% |
Volatility is currently expanding
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations/Events section.
Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity.
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo.
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARCT and any ticker you trade — then tracks every position and per-strategy win rate.
